Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Medroxyprogesterone | |
| Synonyms |
6Alpha-methyl-17alpha-hydroxyprogesterone 6Alpha-methyl-4-pregnen-17alpha-ol-3,20-dione MEDROXYPROGESTERONE Medroxyprogesterone 17Alpha-hydroxy-6alpha-methylprogesterone medroxyprogesterone (6Alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione Curretab |
|
| Definitions |
A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C629 |
|
| Accepted_Therapeutic_Use_For |
Breast carcinoma; Contraception; Endometrial carcinoma; Renal cell carcinoma
|
|
| ALT_DEFINITION |
A hormonal anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called progestins.
|
|
| CAS_Registry |
520-85-4
|
|
| CHEBI_ID |
CHEBI:6715
|
|
| Chemical_Formula |
C22H32O3
|
|
| code |
C629
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)
|
|
| Display_Name |
Medroxyprogesterone
|
|
| FDA_UNII_Code |
HSU1C9YRES
|
|
| FULL_SYN |
6Alpha-methyl-17alpha-hydroxyprogesterone 6Alpha-methyl-4-pregnen-17alpha-ol-3,20-dione MEDROXYPROGESTERONE Medroxyprogesterone 17Alpha-hydroxy-6alpha-methylprogesterone medroxyprogesterone (6Alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione Curretab
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Medroxyprogesterone
|
|
| Legacy Concept Name |
Medroxyprogesterone
|
|
| Maps_To |
Medroxyprogesterone
|
|
| NCI_Drug_Dictionary_ID |
39813
|
|
| NSC Number |
27408
|
|
| PDQ_Closed_Trial_Search_ID |
39813
|
|
| PDQ_Open_Trial_Search_ID |
39813
|
|
| Preferred_Name |
Medroxyprogesterone
|
|
| prefixIRI |
Thesaurus:C629
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C0025147
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |